EICHOR

Recruiting studies: Metastatic Adenocarcinoma Of The Pancreas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Met
Phase 1/Phase 2 · 3 location(s) · GI Innovation, Inc. · NCT07172802 Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Phase 2 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03977233 The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Phase 3 · 3 location(s) · Quercis Pharma AG · NCT06861088 A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06261359 A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 · 21 location(s) · Clasp Therapeutics, Inc. · NCT06778863 A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695 Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherap
Phase 1/Phase 2 · 4 location(s) · Auricula Biosciences Inc. · NCT07148128 iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03608631 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798 Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherap
Phase 3 · 28 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06897644 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/Phase 2 · 18 location(s) · Tango Therapeutics, Inc. · NCT06922591 Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase 1 · 18 location(s) · AstraZeneca · NCT06218914 TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Phase 1/Phase 2 · 5 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT07284277 A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043 A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · 30 location(s) · Pfizer · NCT07090499 Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Meta
Phase 1 · 7 location(s) · Oncomatryx Biopharma S.L. · NCT07377045 Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxe
Phase 1/Phase 2 · 4 location(s) · Onconic Therapeutics Inc. · NCT05257993 Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT07214298 Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
Phase N/A · 1 location(s) · Institut Paoli-Calmettes · NCT07664891 Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
NA · 6 location(s) · Jon Unosson · NCT06065891 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatmen
Phase 3 · 5 location(s) · Revolution Medicines, Inc. · NCT07621718 A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarci
Phase 1/Phase 2 · 4 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07235202 Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metasta
Phase 2 · 2 location(s) · Medical University of South Carolina · NCT07076212 IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657 CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035 Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3 · 15 location(s) · SOFIE · NCT07217717 MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06648434 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap
Phase 3 · 48 location(s) · Astellas Pharma Global Development, Inc. · NCT07409272 AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Phase 1 · 39 location(s) · Amgen · NCT07094113 A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and
Phase 1 · 2 location(s) · Boryung Pharmaceutical Co., Ltd · NCT06867497

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →